Zydus Lifesciences Financial Statements

Name: Zydus Lifesciences Financials — historical data
Creator: StockeZee

For Mar 2026, Zydus Lifesciences reported revenue of ₹27,148 crore and net profit of ₹5,040 crore. Return on equity stands at 21.20%. Profit & loss, balance sheet and cash flow across 9 reported years are below.

Updated 31 Jul 2026Source: NSE & BSE company filingsNifty 100 constituent

Latest year revenue: ₹27,148 Cr
EBITDA: ₹8,475 Cr
Operating margin: 31.22%
Profit after tax: ₹5,040 Cr
Net margin: 18.56%
EPS: ₹50.09
Latest year: Mar 2026
Years reported: 9

Zydus Lifesciences profit & loss

Reported annual performance for Zydus Lifesciences, oldest to newest. Figures in ₹ crore unless a row states otherwise.

Zydus Lifesciences annual profit and loss statement. Figures in ₹ crore unless a row states otherwise.
Line item	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue from Operations	11,936	13,166	14,253	15,102	15,265	17,237	19,547	23,242	27,148
Sales Growth YoY %	—	10.3%	8.26%	5.96%	1.08%	12.92%	13.4%	18.9%	16.81%
Other Income	113	201	114	37	225	187	284	270	510
Total Income	12,050	13,367	14,367	15,139	15,490	17,424	19,832	23,511	27,658
Cost of Goods Sold (COGS)	4,154	4,716	4,920	5,210	5,545	6,310	6,228	6,338	7,293
Cost of Materials Consumed	2,555	2,674	3,460	3,888	4,043	4,123	4,581	4,373	5,110
Purchases of Stock-in-Trade	1,914	2,152	1,554	1,471	1,865	1,949	1,898	2,150	3,071
Changes in Inventories	-315	-110	-94	-149	-362	238	-250	-185	-888
Gross Profit	7,783	8,449	9,333	9,892	9,720	10,927	13,319	16,904	19,856
Gross Margin %	65.2%	64.18%	65.48%	65.5%	63.67%	63.39%	68.14%	72.73%	73.14%
Total Operating Expenses	4,935	5,476	6,550	6,551	6,379	7,067	7,935	9,845	11,381
Employee Benefit Expense	1,855	2,124	2,415	2,490	2,434	2,766	3,138	3,681	4,418
Other Expenses	3,081	3,352	4,135	4,061	3,945	4,302	4,797	6,164	6,963
EBITDA	2,848	2,973	2,783	3,341	3,341	3,860	5,384	7,059	8,475
OPM %	23.86%	22.58%	19.53%	22.12%	21.88%	22.39%	27.54%	30.37%	31.22%
Total Non-Operating Expenses	630	792	675	683	953	248	831	862	1,330
Depreciation & Amortisation	539	599	697	725	713	723	764	916	1,408
Finance Costs	91	194	342	164	127	130	81	166	439
Exceptional Items (Before Tax)	0	0	-364	-205	113	-604	-14	-220	-517
Profit Before Tax (PBT)	2,331	2,382	1,495	2,285	2,838	2,590	4,809	6,027	6,621
Tax Expense	564	530	320	147	512	588	978	1,412	1,595
Current Tax	644	607	238	466	442	690	1,493	2,049	1,380
Deferred Tax	-79	-77	82	-318	70	-103	-515	-637	215
Effective Tax %	24.21%	22.26%	21.39%	6.44%	18.03%	22.7%	20.33%	23.43%	24.09%
Profit/Loss from Discontinued Operations	-19	0	0	0	2,246	-5	23	0	0
Total Profit for Period	1,810	1,899	1,204	2,185	4,618	2,092	3,973	4,673	5,124
Less: Non-controlling Interests	35	50	28	51	131	132	3,860	4,526	84
Net Profit (Owner's PAT)	1,776	1,849	1,177	2,134	4,487	1,960	113	147	5,040
Net Profit Margin %	14.88%	14.04%	8.26%	14.13%	29.4%	11.37%	0.58%	0.63%	18.56%
PAT Growth YoY %	—	4.11%	-36.36%	81.34%	110.32%	-56.31%	-94.22%	29.83%	3,326.24%
Earnings Per Share (EPS)	₹17.35	₹18.06	₹11.49	₹20.84	₹43.83	₹19.37	₹1.13	₹1.46	₹50.09
Diluted Shares Outstanding (Cr.)	102	102	102	102	102	101	101	101	101
Profit/Loss from Associates	63	47	29	47	46	95	118	58	97
Other Comprehensive Income (Net of Tax)	20	-168	-301	73	-105	-314	-200	-100	-775
Expenses	9,719	10,985	12,872	12,855	12,652	14,834	15,023	17,484	21,037
Material Cost %	21.4%	20.31%	24.27%	25.75%	26.48%	23.92%	23.43%	18.82%	18.82%
Employee Cost %	15.54%	16.13%	16.94%	16.49%	15.95%	16.04%	16.05%	15.84%	16.27%
Other Cost %	25.81%	25.46%	29.01%	26.89%	25.84%	24.96%	24.54%	26.52%	25.65%
Interest Coverage (x)	25.34	12.27	6.11	16	20.69	24.15	56.9	37.03	16.1

Zydus Lifesciences revenue and profit trend

Reported annual revenue and net profit, oldest to newest. Two panels because the two measures live on different scales — one shared axis would distort both.

Zydus Lifesciences balance sheet

Assets, liabilities and shareholders' equity as reported, in Schedule III order. Figures in ₹ crore unless a row states otherwise.

Zydus Lifesciences annual balance sheet with assets, liabilities and equity. Figures in ₹ crore unless a row states otherwise.
Line item	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Equity	11,679	11,710	14,930	19,054	19,688	22,102	26,358	29,582
Equity Share Capital	102	102	102	102	101	101	101	101
Reserves & Surplus	10,284	10,273	12,890	16,897	17,415	19,729	23,853	27,011
Equity Method Investments	348	352	357	374	417	416	1,143	1,167
Total Equity	11,679	11,710	14,930	19,054	19,688	22,102	26,358	29,582
Non-Current Liabilities	4,461	3,707	1,094	902	537	1,837	1,802	7,113
Long-term Borrowings	3,950	3,215	610	362	—	—	—	3,188
Deferred Tax Liabilities	252	210	120	154	194	447	513	1,734
Non-Current Provisions	184	235	310	325	272	310	384	445
Other Non-Current Liabilities	3	2	1	0	20	2	1	1
Non-Current Financial Liabilities	4,022	3,260	664	423	51	1,079	904	4,933
Current Liabilities	7,343	8,269	7,861	7,827	5,527	5,340	9,042	15,712
Short-term Borrowings	3,197	3,827	3,071	3,834	1,163	769	3,170	8,582
Trade Payables	1,923	2,031	2,206	2,138	2,125	2,127	2,306	2,845
Current Financial Liabilities	6,982	7,807	7,265	7,233	4,722	4,295	7,708	14,389
Other Current Financial Liabilities	1,862	1,949	1,988	1,261	1,434	1,400	2,233	2,963
Other Current Liabilities	171	190	178	186	282	278	266	478
Current Provisions	136	243	330	366	365	395	451	479
Liabilities Held for Sale	—	—	—	13	4	2	—	—
Current Tax Liabilities	54	29	88	42	157	372	616	366
Total Liabilities	11,804	11,976	8,955	8,742	6,068	7,179	10,843	22,824
Total Non-Current Assets	14,985	14,971	15,169	15,534	15,740	17,779	20,156	32,501
Property, Plant & Equipment (PPE)	5,106	5,452	5,550	5,762	5,697	5,803	6,042	9,231
Capital Work-in-Progress	837	742	783	661	1,130	1,112	1,318	1,166
Intangible Assets	1,769	1,387	1,236	1,127	1,020	1,299	1,850	7,332
Non-Current Investments	95	201	274	561	511	552	414	598
Loans – Non-Current	—	—	—	—	2	—	—	0
Other Non-Current Assets	346	308	295	344	329	197	389	789
Non-Current Financial Assets	319	487	526	805	1,011	730	455	632
Net Fixed Assets	7,712	7,581	7,570	7,550	7,847	8,214	9,210	17,729
Total Current Assets	8,498	8,715	8,716	12,095	10,008	11,420	17,046	19,906
Inventories	2,688	2,789	3,236	3,719	3,413	3,442	3,944	5,628
Trade Receivables	3,951	3,663	3,127	3,340	4,417	5,220	4,025	5,416
Cash & Cash Equivalents	421	845	665	658	488	413	827	855
Current Investments	230	213	199	2,353	619	253	4,851	5,776
Loans – Current	10	—	—	—	0	2	77	4
Current Financial Assets	4,961	5,072	4,449	7,467	5,838	7,237	12,423	12,829
Other Current Assets	849	855	1,031	909	757	741	679	1,449
Other Current Financial Assets	121	231	234	666	228	657	513	217
Assets Held for Sale	—	—	—	166	8	82	—	—
Net Working Capital	1,156	446	855	4,268	4,482	6,080	8,004	4,194
Additional Asset Fields	2,263	2,188	3,012	3,150	3,435	3,916	4,749	4,579
Def Tax Assets	970	853	1,074	1,096	1,262	1,644	2,344	2,109
Non Controlling Int	1,293	1,335	1,937	2,054	2,173	2,272	2,405	2,471
Total Assets	23,483	23,687	23,885	27,795	25,756	29,281	37,202	52,407
Total Borrowings	7,147	7,041	3,680	4,196	1,163	769	3,170	11,770
Net Debt	6,726	6,196	3,015	3,538	675	356	2,343	10,914
Debt to Equity (x)	0.61	0.6	0.25	0.22	0.06	0.03	0.12	0.4
Current Ratio (x)	1.16	1.05	1.11	1.55	1.81	2.14	1.89	1.27

Zydus Lifesciences cash flow statement

Cash generated and used across operating, investing and financing activities. Figures in ₹ crore unless a row states otherwise.

Zydus Lifesciences annual cash flow statement across operating, investing and financing activities. Figures in ₹ crore unless a row states otherwise.
Line item	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Net Cash from Operating Activities	2,078	2,689	3,228	6,777	2,117
Profit Before Tax	2,838	2,590	4,809	6,027	6,621
Depreciation & Amortisation	736	723	764	916	1,408
Finance Costs	114	126	76	160	365
Working Capital Changes	-283	-289	-833	1,609	-2,623
Tax Paid	-675	-592	-1,286	-1,802	-1,591
Net Cash from Investing Activities	1,154	1,171	-1,475	-8,372	-8,296
Purchase of PPE	-1,203	-1,031	-907	-1,713	-3,394
Sale of Fixed Assets	-636	-211	-334	51	25
Interest Received	58	77	127	182	427
Net Cash from Financing Activities	-868	-4,400	-1,804	2,031	5,997
Proceeds from Borrowings	1,037	155	0	2,402	8,260
Repayment of Borrowings	-1,421	-3,302	-393	0	-968
Interest Paid	-111	-126	-73	-90	-354
Dividend Paid	-372	-267	-621	-303	-1,106
Buyback / Redemption of Shares	0	-863	-725	0	0
Lease Liabilities Paid	0	3	1	4	-26
Net Change in Cash	2,373	-534	-75	414	28
Effect of Foreign Exchange Changes	9	7	-23	-21	211
Free Cash Flow	876	1,658	2,321	5,064	-1,277
CFO / PBT (x)	0.73	1.04	0.67	1.12	0.32

Zydus Lifesciences key ratios

Valuation, profitability, return, leverage and per-share measures computed from reported statements — not from adjusted or normalised earnings.

Zydus Lifesciences trades at a P/E of 22.23× against a sector median of 42.68× — a 48% discount. Sector comparisons can mislead for conglomerates with mixed business lines.

Zydus Lifesciences valuation, profitability, return and leverage ratios
Ratio	Category	Value
P/E (TTM)	Valuation	22.23
Forward P/E	Valuation	23.26
P/B	Valuation	4.13
PEG (TTM)	Valuation	0.59
EV / EBITDA (TTM)	Valuation	15.04
P/S (TTM)	Valuation	4.26
Operating margin	Profitability	31.2%
Net margin (TTM)	Profitability	18.36%
Return on equity	Return ratios	21.2%
Return on capital employed	Return ratios	21.1%
Return on assets	Return ratios	8.07%
Debt to equity	Leverage & liquidity	0.46
Beta	Leverage & liquidity	0.74
EPS (TTM)	Per share	₹50.1
Book value	Per share	₹269
Revenue / share (TTM)	Per share	₹270.4
Cash flow / share	Per share	₹21.22
Dividend yield	Shareholder returns	0.09%
Dividend payout (TTM)	Shareholder returns	21.98%

How this is calculated

Statements are as filed with the exchanges. Consolidated figures are shown where reported. Figures are in rupees crore unless the table states otherwise. Ratios are computed from the same reported statements, not from adjusted or normalised earnings.

Index membership reflects the Nifty 100 as published by NSE Indices, effective 2026-03-30.

Zydus Lifesciences: frequently asked questions

What is Zydus Lifesciences's annual revenue?

Zydus Lifesciences reported revenue of ₹27,148 crore in Mar 2026, up 16.8% on the previous financial year.

Is Zydus Lifesciences profitable?

Zydus Lifesciences reported a net profit of ₹5,040 crore in Mar 2026, up 3326.2% on the previous financial year.

What is Zydus Lifesciences's EPS?

Zydus Lifesciences reported earnings per share of ₹50.09 for Mar 2026.

What is Zydus Lifesciences's operating margin?

Zydus Lifesciences's operating margin for Mar 2026 was 31.22%.

What is Zydus Lifesciences's return on equity?

Zydus Lifesciences's return on equity stands at 21.20%. ROE measures profit generated per rupee of shareholder equity.

How many years of Zydus Lifesciences financials are shown?

9 reported financial years are tabulated on this page, the most recent being Mar 2026.

Are these figures consolidated or standalone?

Consolidated figures are shown wherever the company reports them, and standalone otherwise. The basis in use is labelled on the statement table.

More Zydus Lifesciences data

Compare financial statements with peers

Explore

Comparing financial statements across companies is more useful than reading one in isolation — the peer links above open the same view for Zydus Lifesciences’s closest listed competitors.

Disclaimer

The data, ratios and commentary about Zydus Lifesciences Ltd (ZYDUSLIFE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.